Notably, AAV-based therapies, such as Luxturna (using AAV2 for RPE65 mutations causing Leber congenital amaurosis) and Zolgensma (using AAV9 for spinal muscular atrophy by replacing the SMN1 gene), have shown remarkable therapeutic outcomes [26]. The gene discussed is SMN1; the disease is spinal muscular atrophy.